SG10201503450WA - Vaccine against beta-herpesvirus infection and use thereof - Google Patents

Vaccine against beta-herpesvirus infection and use thereof

Info

Publication number
SG10201503450WA
SG10201503450WA SG10201503450WA SG10201503450WA SG10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA
Authority
SG
Singapore
Prior art keywords
vaccine against
herpesvirus infection
against beta
beta
herpesvirus
Prior art date
Application number
SG10201503450WA
Other languages
English (en)
Inventor
Thirion Christian
Koszinowski Ulrich
A Mohr Christian
Ruzsics Zsolt
Original Assignee
Thirion Christian
Koszinowski Ulrich
A Mohr Christian
Ruzsics Zsolt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thirion Christian, Koszinowski Ulrich, A Mohr Christian, Ruzsics Zsolt filed Critical Thirion Christian
Publication of SG10201503450WA publication Critical patent/SG10201503450WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C12N2710/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201503450WA 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof SG10201503450WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004751 2010-05-05
EP10005045 2010-05-12

Publications (1)

Publication Number Publication Date
SG10201503450WA true SG10201503450WA (en) 2015-06-29

Family

ID=44146744

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012080891A SG185121A1 (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof
SG10201503450WA SG10201503450WA (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012080891A SG185121A1 (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Country Status (8)

Country Link
US (3) US9078867B2 (enExample)
EP (1) EP2566957B8 (enExample)
JP (2) JP2013527758A (enExample)
AU (1) AU2011250191A1 (enExample)
CA (2) CA3128572C (enExample)
ES (1) ES2679245T3 (enExample)
SG (2) SG185121A1 (enExample)
WO (1) WO2011138040A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187585A1 (en) * 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
DK2772265T3 (en) 2010-05-14 2018-04-30 Univ Oregon Health & Science Recombinant HCMV and RHCMV vectors and uses thereof
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
EP2964769B1 (en) 2013-03-05 2018-08-22 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
US20160243216A1 (en) * 2013-10-29 2016-08-25 The University Of Sydney Cmv immuno-stimulatory composition
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
MX2017010027A (es) 2015-02-10 2018-08-15 Univ Oregon Health & Science Métodos y composiciones útiles en la generación de respuestas de células t cd8+ no canónicas.
CN116926128A (zh) 2015-11-20 2023-10-24 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
SG11201903340TA (en) 2016-10-18 2019-05-30 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
WO2020014222A2 (en) * 2018-07-09 2020-01-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Viral promoters and compositions and methods of use thereof
AU2019304526B2 (en) * 2018-07-20 2024-09-19 Aicuris Anti-Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
US20230364215A1 (en) * 2020-10-02 2023-11-16 Colorado State University Research Foundation Compositions comprising inactivated microbes, and methods for use and production thereof
CN116042526B (zh) * 2022-07-04 2023-11-10 北京肿瘤医院(北京大学肿瘤医院) P16基因特异性甲基化的正常人永生化结肠成纤维细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
WO2005012545A2 (en) * 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
EP2497831B1 (en) * 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors

Also Published As

Publication number Publication date
CA3128572A1 (en) 2011-11-10
US9078867B2 (en) 2015-07-14
CA2798214A1 (en) 2011-11-10
US20190117766A1 (en) 2019-04-25
WO2011138040A3 (en) 2012-10-26
EP2566957B8 (en) 2018-06-06
JP2016136950A (ja) 2016-08-04
US10842863B2 (en) 2020-11-24
AU2011250191A1 (en) 2012-11-22
EP2566957A2 (en) 2013-03-13
EP2566957B1 (en) 2018-04-18
US20150306210A1 (en) 2015-10-29
WO2011138040A8 (en) 2012-12-20
JP2013527758A (ja) 2013-07-04
CA2798214C (en) 2021-10-19
ES2679245T3 (es) 2018-08-23
SG185121A1 (en) 2012-11-29
CA3128572C (en) 2023-02-21
JP6427514B2 (ja) 2018-11-21
WO2011138040A2 (en) 2011-11-10
US20130202638A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
SG10201503450WA (en) Vaccine against beta-herpesvirus infection and use thereof
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
SI2539326T1 (sl) Bisaril-vezani ariltriazoloni in njihova uporaba
IL215389A0 (en) Pneumococcal vaccine and uses thereof
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
GB201010193D0 (en) Medicinal use
ZA201208173B (en) Peptices and their use
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
ZA201209411B (en) Vaccine and methods to reduce campylobacter infection
PL2521445T3 (pl) Preparat i jego zastosowanie
ZA201304012B (en) Novel compound and medical use thereof
PL2552440T3 (pl) Nowa kombinacja i zastosowanie
ZA201301950B (en) Bvdv vaccine
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201006479D0 (en) Garment and use thereof
EP2650292A4 (en) THIAZOLAMINE DERIVATIVE AND ITS PHARMACEUTICAL APPLICATIONS FOR SMALL RNA VIRAL INFECTIONS
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201008286D0 (en) Device and use
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
ZA201302154B (en) Vaccine
GB201006380D0 (en) Excipients and their use
GB201012283D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201007588D0 (en) Vaccine